DVAX
Dynavax Technologies CorporationNASDAQHealthcare$15.50+0.00%ClosedMarket Cap: $1.82B
As of 2026-04-04
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
3.40
P/S
5.51
EV/EBITDA
-75.83
DCF Value
$-22.27
FCF Yield
4.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
83.2%
Operating Margin
3.2%
Net Margin
-13.1%
ROE
-8.1%
ROA
-4.6%
ROIC
1.2%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $94.9M | $26.9M | $0.21 |
| Q2 2025 | $95.4M | $18.7M | $0.14 |
| Q1 2025 | $68.2M | $-96.1M | $-0.77 |
| Q4 2024 | $72.0M | $7.0M | $0.05 |
Analyst Ratings
View AllWilliam BlairMarket Perform
2025-12-24JMP SecuritiesMarket Outperform
2025-08-22JMP SecuritiesMarket Outperform
2025-05-07Goldman SachsSell
2025-04-17Trading Activity
Insider Trades
View AllDeep Track Biotechnology Master Fund, Ltd.10 percent owner
SellWed Feb 11
Spencer Ryandirector, officer: CEO and Director
SellTue Feb 10
Spencer Ryandirector, officer: CEO and Director
SellTue Feb 10
Spencer Ryandirector, officer: CEO and Director
SellTue Feb 10
Spencer Ryandirector, officer: CEO and Director
SellTue Feb 10